etoposide has been researched along with xav939 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, S; Fan, J; Hou, W; Tian, X; Tong, H; Xu, H | 1 |
| Crowe, DL; Wu, J | 1 |
2 other study(ies) available for etoposide and xav939
| Article | Year |
|---|---|
XAV939 inhibits the stemness and migration of neuroblastoma cancer stem cells via repression of tankyrase 1.
Topics: AC133 Antigen; Antigens, CD; Cell Movement; Enzyme Inhibitors; Etoposide; Gene Expression Regulation, Neoplastic; Glycoproteins; Heterocyclic Compounds, 3-Ring; Humans; Neoplastic Stem Cells; Neuroblastoma; Peptides; Tankyrases; Tumor Cells, Cultured | 2014 |
PARP5B is required for nonhomologous end joining during tumorigenesis in vivo.
Topics: Animals; Carcinogens; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA End-Joining Repair; Down-Regulation; Etoposide; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Heterocyclic Compounds, 3-Ring; Humans; Loss of Function Mutation; Mice; Neoplasm Invasiveness; Squamous Cell Carcinoma of Head and Neck; Tankyrases | 2022 |